Tag Archive for: Merck

As a co-investor in the USD 25 million Series B round, Beiersdorf AG is signalling that artificial intelligence is becoming strategically important for skin research. The Hamburg-based group is participating through its venture unit in the AI biotech Turbine, founded in Budapest and now also headquartered in London.

A surprise move from Darmstadt to Paris: outgoing Merck CEO Belén Garijo is set to take the helm at French pharmaceutical group Sanofi after Paul Hudson unexpectedly failed to secure a contract extension from the board.

This article examines the critical success factors for PEGylated therapies and the decision-making process for when a custom PEG may be warranted rather than an off-the-shelf solution. The essential role of a contract development and manufacturing organization (CDMO) with deep expertise in activated PEG chemistry is highlighted.
Authors: Raymond Behrendt, Silvia Kaden-Vagt, Lotfi Bouchekioua, Merck KGaA, Darmstadt, Germany

In the race to replace MSD’s mega blockbuster pembrolizumab with a more effective bispecific VEGF x PD-(L)1 antibody, German company BioNTech SE has struck a good deal. BioNTech is now developing its Phase III programme BNT327, acquired with the US$950m takeover of Chinese company Biotheus Co Ltd, with Bristol Myers Squibb (BMS) in return for a payment of US$11.1bn.